Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 11 September 2020 to Question 84242 on Coronavirus: Vaccination, if he will list those six supply agreements.

The UK Government has secured early access to 340 million vaccines doses through agreements with six separate vaccine developers. This includes agreements with:

• BioNTech/Pfizer for 30 million doses.
• Oxford/AstraZeneca who will work to supply 100 million doses of the vaccine being developed by Oxford University.
• GlaxoSmithKline and Sanofi Pasteur to buy 60 million doses.
• Novavax for 60 million doses alongside funding of their Phase 3 clinical trial.
• Janssen for 30 million doses of their not-for-profit vaccine.
• Valneva for 60 million doses, with an option to acquire a further 130 million if the vaccine is proven to be safe, effective and suitable.